Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN 24 FE versus NORINYL 1 35 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN 24 FE versus NORINYL 1 35 21 DAY.
LOESTRIN 24 FE vs NORINYL 1+35 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation. Increases cervical mucus viscosity, reducing sperm penetration. Alters endometrial development, decreasing implantation likelihood.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin release (FSH, LH) via negative feedback on hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial structure to impair sperm penetration and implantation.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 24 days, followed by a low-dose iron-containing tablet (75 mg ferrous fumarate) for 4 days.
One tablet orally once daily for 21 consecutive days, followed by 7 days off therapy.
None Documented
None Documented
Norethindrone: 5-12 hours; Ethinyl estradiol: 13-27 hours. The terminal half-life supports once-daily dosing; steady state is achieved within 5-7 days.
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady state achieved by day 10-14.
Ethinyl estradiol and norethindrone are primarily excreted in urine (about 50-60%) and feces (about 30-40%) as glucuronide and sulfate conjugates after hepatic metabolism.
Renal (50-60% as metabolites, primarily glucuronide and sulfate conjugates) and fecal (30-40% as metabolites). Less than 1% excreted unchanged.
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive